Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with polycystic ovary syndrome: A meta-analysis

Molecular Biology Reports

Volumn 39, Issue 10, 2012, Pages 9649-9660

  Tang, Song Tao ^a   Wang, Chang Jiang ^a   Tang, Hai Qin ^a   Peng, Wen Jia ^a   Wang, You Min ^a   Zhang, Qiu ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Peroxisome proliferator activated receptor (PPAR); Polycystic ovary syndrome (PCOS); Polymorphism

Indexed keywords

ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE;

ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); OVARY POLYCYSTIC DISEASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2 GENE; POLYMERASE CHAIN REACTION; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY ANALYSIS;

AMINO ACID SUBSTITUTION; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; ODDS RATIO; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, GENETIC; PPAR GAMMA;

EID: 84868595472     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-1830-6     Document Type: Article

References (34)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81(1):19-25
2. Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38(9):1165-1174
3. Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18(6):774-800
4. Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84(1):165-169
5. Wild S, Pierpoint T, McKeigue P, Jacobs H (2000) Cardiovascular disease in women with polycystic ovary syndrome at longterm follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 52(5):595-600
6. Franks S, Gharani N, McCarthy M (2001) Candidate genes in polycystic ovary syndrome. Hum Reprod Update 7(4):405-410
7. Wang Y, Wu X, Cao Y, Yi L, Fan H, Chen J (2006) Polymorphisms of the peroxisome proliferator-activated receptor-gamma and its coactivator-1alpha genes in Chinese women with polycystic ovary syndrome. Fertil Steril 85(5):1536-1540
8. Deeb SS, Fajas L, Nemoto M et al (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20(3):284-287
9. Jacob S, Stumvoll M, Becker R et al (2000) The PPARgamma2 polymorphism pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Horm Metab Res 32(10):413-416
10. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351(11):1106-1118
11. Huguenin GV, Rosa G (2010) The Ala allele in the PPARgamma2 gene is associated with reduced risk of type 2 diabetes mellitus in Caucasians and improved insulin sensitivity in overweight subjects. Br J Nutr 104(4):488-497
12. Hahn S, Fingerhut A, Khomtsiv U et al (2005) The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 62(5):573-579
13. Orio F Jr, Matarese G, Di Biase S et al (2003) Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab 88(12):5887-5892
14. Orio F Jr, Palomba S, Cascella T et al (2004) Lack of an association between peroxisome proliferator-activated receptorgamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab 89(10):5110-5115
15. San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF (2004) Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 89(6):2640-2646
16. Tok EC, Aktas A, Ertunc D, Erdal EM, Dilek S (2005) Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-gamma2 Pro12Ala genotype. Hum Reprod 20(6):1590-1595
17. Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA (2002) Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro (12) Ala polymorphism in the PPAR gamma gene. J Clin Endocrinol Metab 87(2):772-775
18. Korhonen S, Heinonen S, Hiltunen M et al (2003) Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Hum Reprod 18(3):540-543
19. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177-188
20. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719-748
21. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539-1558
22. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629-634
23. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088-1101
24. Yilmaz M, Ergün MA, Karakoç A, Yurtçu E, Cakir N, Arslan M (2006) Pro12Ala polymorphism of the peroxisome proliferatoractivated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol Endocrinol 22(6):336-342
25. Christopoulos P, Mastorakos G, Gazouli M et al (2010) Peroxisome proliferator-activated receptor-gamma and-delta polymorphisms in women with polycystic ovary syndrome. Ann N Y Acad Sci 1205(Sep):185-191
26. Haap M, Machicao F, Stefan N et al (2005) Genetic determinants of insulin action in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 113(5):275-281
27. Bidzinska-Speichert B, Lenarcik A, Tworowska-Bardzinska U et al (2011) Pro12Ala PPAR gamma2 gene polymorphism in women with polycystic ovary syndrome. Ginekol Pol 82(6):426-429
28. Koika V, Marioli DJ, Saltamavros AD, Vervita V, Koufogiannis KD, Adonakis G et al (2009) Association of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma2 with decreased basic metabolic rate in women with polycystic ovary syndrome. Eur J Endocrinol 161(2):317-322
29. Xita N, Lazaros L, Georgiou I, Tsatsoulis A (2009) The Pro12Ala polymorphism of the PPAR-gamma gene is not associated with the polycystic ovary syndrome. Hormones (Athens) 8(4):267-272
30. Chae SJ, Kim JJ, Choi YM, Kim JM, Cho YM, Moon SY (2010) Peroxisome proliferator-activated receptor-gamma and its coactivator-1alpha gene polymorphisms in Korean women with polycystic ovary syndrome. Gynecol Obstet Invest 70(1):1-7
31. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG (2001) Replication validity of genetic association studies. Nat Genet 29(3):306-309
32. Hegele RA, Cao H, Harris SB, Zinman B, Hanley AJ, Anderson CM (2000) Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 85(5):2014-2019
33. Chen S, Yan W, Huang J, Yang W, Gu D (2004) Peroxisome proliferator-activated receptor-gamma coactivator-1alpha polymorphism is not associated with essential hypertension and type 2 diabetes mellitus in Chinese population. Hypertens Res 27(11):813-820
34. Kao WH, Coresh J, Shuldiner AR, Boerwinkle E, Bray MS, Brancati FL (2003) Pro12Ala of the peroxisome proliferatoractivated receptor-gamma2 gene is associated with lower serum insulin levels in nonobese African Americans: the atherosclerosis risk in communities study. Diabetes 52(6):1568-1572